Career Transition in Industry: Why, When and How?

Thank you

This live web event has ended. Thank you for attending.

Description

Career transitions are huge milestones for anyone and there can be countless factors to take into account when considering one. Often times we run into situations where we might be thinking of switching jobs but are not sure if we are making the right decisions. In this webinar, the PPDM community would like to invite two seasoned scientists from industry who have had some very successful career transitions and also have experienced different company sizes and setup. We would like to learn from their experience and seek advice in a form of panel discussion on topics related to career transitions within industry. Some of the key questions we would like to address are:

What would you say is the most important thing that someone should seek for when considering a career transition?
What would indicate a good or bad timing for a career transition?
Would you have a cautionary tale for someone thinking of a career transition?
What are the resources for someone thinking of a career transition? Network? Recruiter? Conferences? Mentor?
How was your transition between big and small companies? Can you describe the differences you felt and what you personally prefer?
Thinking back, can you point to the best transition you had in your career? Also the worst if you don’t mind?
What’s your top advice for someone thinking of a career transition?

Contributors

Yang Chen, Ph.D.

Yang is currently Senior Director of Quantitative Clinical Pharmacology at Daiichi Sankyo, supporting oncology drug development. Prior to joining Daiichi Sankyo, she worked at EpimAb Biotherapeutics and Janssen Pharmaceuticals where her work focused on utilizing modeling &simulation to support antibody drug development at various stages in immunology and oncology therapeutic areas. Yang has also worked at Novartis and Wyeth wherein she has gained clinical pharmacology expertise in both antibody therapeutics, including biosimilars, and small molecule drug development in both oncology and CNS neuroscience therapeutic areas. Yang also gives lectures on Antibody PK/PD at Rutgers University and University of Iowa. Yang received her B.S. in Pharmacy from Peking University, China; M.S. in Pharmacometrics and Ph.D. in Pharmaceutical Sciences from the University at Buffalo.
Amitava Mitra, Ph.D., FAAPS

Amitava is currently Senior Director of Clinical Pharmacology at Kura Oncology, where he supports global drug development programs. He has 16 years of experience in the pharmaceutical industry supporting various therapeutic areas and has previously worked at Merck, Novartis and J&J. Amitava has a PhD in Pharmaceutical Sciences from University of Maryland, Baltimore. Amitava’s main research interests include clinical pharmacology, modeling & simulation, pharmacokinetics, and biopharmaceutics. He has interacted with several regulatory agencies like FDA, EMA and PMDA on these topics. Amitava has published more than 50 research and review articles and has more than 30 podium presentations in national & international conferences. Amitava has won several awards including the Novartis VIVA Leading Science award in 2019 for his modeling efforts, an award that celebrates exceptional contribution by scientists across the company’s R&D organization worldwide. Amitava actively volunteers in AAPS and ASCPT, and has participated in consortia such as IQ and IMI. Amitava teaches a course on Clinical Pharmacology at University of Maryland School of Pharmacy.

Thank you

Description

Contributors

Yang Chen, Ph.D.

Amitava Mitra, Ph.D., FAAPS